$CBRS

This Hot Artificial Intelligence IPO Stock Is Down 52%, but It Could Double From Here, According to Wall Street

Cerebras (NASDAQ: CBRS), an AI chipmaker, saw its stock drop 52% since its May IPO. Analysts remain bullish, with a median price target of $295, double its current price. The decline followed a shift to cloud services and concerns about OpenAI's use of Nvidia GPUs. Cerebras has a $25.4B backlog, primarily from OpenAI, but faces execution risks in its new business model.

Original reporting
Published Oct 16, 2026, 9:17 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 9:37 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
This Hot Artificial Intelligence IPO Stock Is Down 52%, but It Could Double From Here, According to Wall Street — source image
Decision brief

The 30-second read

$CBRSBearishLow
01

Why it matters

The earnings miss and customer concentration risk create near‑term downside pressure, but the large contracted backlog offers long‑term upside if execution improves.

02

Market read

The story underscores execution challenges for newer AI‑chip firms and may influence sentiment toward the sector.

03

What to watch

The $20 billion OpenAI backlog and the company's supply‑chain resilience may mitigate short‑term concerns.

Relevance 4/10Novelty 2/10Timing: post‑earnings recap

Background

Cerebras, a 2026 AI‑chip IPO, saw its share price fall 52% after a Q2 earnings miss and news that OpenAI is using Nvidia GPUs for its newest model.

Company-level read

Ticker impact

$CBRSBearishMedium confidence
Context

The article recaps Cerebras' Q2 earnings miss, a 20% stock plunge, and OpenAI's shift to Nvidia GPUs, which are recent but not first‑reported facts.

Expected impact

downward pressure as investors price in the earnings miss and competitive threat from Nvidia.

Evidence & confidence

Earnings miss and loss of a key customer signal short‑term weakness; no new catalyst suggests limited upside.

Market effects

Highlights execution risk for AI‑chip makers and potential shift of AI workloads to Nvidia.

Limited to US AI‑hardware sector.

Modest, as the story reflects broader AI‑chip competition.

Counterpoint

If Cerebras can scale its cloud services and secure the full OpenAI spend, the stock could rebound.

Key entities

  • Cerebras

    AI‑chip maker listed on NASDAQ (CBRS).

  • OpenAI

    Key AI lab with a multi‑billion‑dollar contract with Cerebras.

Related articles

$CBRSMed

Cerebras stock jumps 9%; Q3 sales guide sets a harder test

Cerebras Systems (CBRS) stock rose 9% after OpenAI's Sam Altman reaffirmed their partnership. The company's Q3 revenue guidance suggests 2.4% sequential growth. OpenAI committed to 750MW of capacity, with an option for 1.25GW. Cerebras reported $56.8M in OpenAI-related revenue in Q2, 31.5% of total GAAP revenue. The stock remains below its IPO price of $185.

$CBRSHigh

CBRS Stock Surges Over 6% in Monday Pre-Market: What's the Sam Altman Connection? - Cerebras Systems (NAS

Cerebras Systems (CBRS) shares rose 6.56% premarket after OpenAI CEO Sam Altman called it a 'close partner,' easing concerns. Analysts noted strong ties with OpenAI, despite Nvidia (NVDA) running its new model. Barclays' Tom O'Malley called the sell-off 'overdone,' while Paul Meeks upgraded CBRS to Buy with a $209 target, citing high AI demand. CBRS is down 52.45% YTD.

$CBRSMed

Mizuho reiterates Cerebras Systems stock rating on inference growth

Mizuho reiterated its Outperform rating and $300 price target for Cerebras Systems (CBRS), citing growth in fast inference workloads. The firm projects a $550B market by 2030, with CBRS trading near its 52-week low at $166.43. CBRS reported 91% revenue growth over the last year, and analysts have revised earnings upwards, though some suggest overvaluation. The company unveiled the CS-4 system, with improved performance and compute density, expected in Q3.